YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways
British Journal of Cancer, Published online: 21 October 2019; doi:10.1038/s41416-019-0604-5YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways
ConclusionPatients with pancreatic cancer with a tumor SUVmax ≥ 7.05 or a CA 19-9 value ≥ 240.55 are likely to have lymph node micrometastases.
Authors: Capula M, Mantini G, Funel N, Giovannetti E Abstract Introduction. Most pancreatic cancer patients are diagnosed at advanced-stages and first-line regimens (FOLFIRINOX and gemcitabine/nab-paclitaxel) provide limited survival advantage and are associated with considerable toxicities. In this grim scenario, novel treatments and biomarkers are warranted.Areas covered. MicroRNAs (miRNAs) emerged as biomarkers for cancer prognosis and chemoresistance and blood-based miRNAs are being evaluated as indicators of therapeutic activity. Moreover, aberrant metabolism, such as aerobic glycolysis, has been correlated to...
Authors: Kim DU PMID: 31724388 [PubMed - in process]
Publication date: Available online 14 November 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Puvanesswaray Ramakrishnan, Wei Mee Loh, Subash C.B. Gopinath, Srinivasa Reddy Bonam, Ismail M. Fareez, Rhanye Mac Guad, Maw Shin Sim, Yuan Seng WuAbstractActivated pancreatic stellate cells (PSCs) have been widely accepted as a key precursor of excessive pancreatic fibrosis, which is a crucial hallmark of chronic pancreatitis (CP) and its formidable associated disease, pancreatic cancer (PC). Hence, anti-fibrotic therapy has been identified as a novel therapeutic strategy for treating CP and PC by targeting PSCs. Most of the a...
Publication date: 14 November 2019Source: Cell, Volume 179, Issue 5Author(s): Avnish Kapoor, Wantong Yao, Haoqiang Ying, Sujun Hua, Alison Liewen, Qiuyun Wang, Yi Zhong, Chang-Jiun Wu, Anguraj Sadanandam, Baoli Hu, Qing Chang, Gerald C. Chu, Ramsey Al-Khalil, Shan Jiang, Hongai Xia, Eliot Fletcher-Sananikone, Carol Lim, Gillian I. Horwitz, Andrea Viale, Piergiorgio Pettazzoni
Condition: Pancreatic Ductal Adenocarcinoma Intervention: Device: EUSRA electrode needle connected to a radiofrequency generator (VIVA RF generator; STARmed, Seoul, S. Korea) Sponsor: Campus Bio-Medico University Not yet recruiting
Conditions: Diabetes Mellitus; Diabetes; Diabetes Mellitus, Type 2; Diabetes type2; Cancer of Pancreas; Pancreas Neoplasm; Pancreas Adenocarcinoma; Pancreatic Cancer Intervention: Sponsors: University of Pecs; Hungarian Pancreatic Study Group (HPSG) Not yet recruiting
Public awareness needs to increase to make sure the disease is picked up early and curb rise in cases, says Oral Health Foundation Related items fromOnMedica NHS must improve access to screening to save lives Third of emergency cancer presenters never saw GP Smartphone apps miss a third of melanomas Public urged to know what pancreatic cancer symptoms to look out for Parents urged to take toddlers for dental check
THURSDAY, Nov. 14, 2019 -- Global burdens of colorectal cancer, pancreatic cancer, inflammatory bowel disease (IBD), and stomach cancer increased from 1990 to 2017, according to four studies published online Oct. 21 in The Lancet Gastroenterology...